(Q40435764)

20 September 2017

title

Combined CD4+ Th1 effect and lymphotactin transgene expression enhance CD8+ Tc1 tumor localization and therapy (English)

1 reference

20 September 2017

Huang H

1

1 reference

20 September 2017

Bi XG

2

1 reference

20 September 2017

Yuan JY

3

1 reference

20 September 2017

Xu SL

4

1 reference

20 September 2017

Guo XL

5

1 reference

20 September 2017

Xiang J

6

1 reference

20 September 2017

publication date

1 June 2005

1 reference

20 September 2017

1 reference

20 September 2017

volume

12

1 reference

20 September 2017

issue

12

1 reference

20 September 2017

page(s)

999-1010

1 reference

Treatment of murine gliomas by adoptive transfer of ex vivo activated tumor-draining lymph node cells

20 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302486

Generation of polarized antigen-specific CD8 effector populations: reciprocal action of interleukin (IL)-4 and IL-12 in promoting type 2 versus type 1 cytokine profiles

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302486

Type 1 and type 2: a fundamental dichotomy for all T-cell subsets

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302486

Perforin and Fas killing by CD8+ T cells limits their cytokine synthesis and proliferation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302486

The expanding universe of T-cell subsets: Th1, Th2 and more.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302486

The role of CD4+ tumor-infiltrating lymphocytes in human solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302486

Interleukin-2 production by tumor cells bypasses T helper function in the generation of an antitumor response

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302486

Help for cytotoxic-T-cell responses is mediated by CD40 signalling

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302486

T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302486

A conditioned dendritic cell can be a temporal bridge between a CD4+ T-helper and a T-killer cell

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302486

Tumor-specific CD4+ T cells have a major "post-licensing" role in CTL mediated anti-tumor immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302486

Lymphotactin: a cytokine that represents a new class of chemokine

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302486

Neutrophils and B cells express XCR1 receptor and chemotactically respond to lymphotactin

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302486

T cell receptor antagonist peptides induce positive selection

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302486

Regression of engineered tumor cells secreting cytokines is related to a shift in host cytokine profile from type 2 to type 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302486

Lymphocyte-mediated cytotoxicity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302486

Synergistic effect of adoptive T-cell therapy and intratumoral interferon gamma-inducible protein-10 transgene expression in treatment of established tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302486

Adoptive tumor therapy with T lymphocytes enriched through an IFN-gamma capture assay.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302486

Adenoviral vectors expressing lymphotactin and interleukin 2 or lymphotactin and interleukin 12 synergize to facilitate tumor regression in murine breast cancer models

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302486

Specific T helper cell requirement for optimal induction of cytotoxic T lymphocytes against major histocompatibility complex class II negative tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302486

Th1 and Th2 cell clones to a poorly immunogenic tumor antigen initiate CD8+ T cell-dependent tumor eradication in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302486

Distinct role of antigen-specific T helper type 1 (Th1) and Th2 cells in tumor eradication in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302486

Dendritic cells engineered to express the Flt3 ligand stimulate type I immune response, and induce enhanced cytoxic T and natural killer cell cytotoxicities and antitumor immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302486

Cell-Associated Ovalbumin Is Cross-Presented Much More Efficiently than Soluble Ovalbumin In Vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302486

Treatment of subcutaneous tumor with adoptively transferred T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302486

7 January 2021

Type 1 and type 2 CD8+ effector T cell subpopulations promote long-term tumor immunity and protection to progressively growing tumor

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302486

7 January 2021

The role of adoptively transferred CD8 T cells and host cells in the control of the growth of the EG7 thymoma: factors that determine the relative effectiveness and homing properties of Tc1 and Tc2 effectors

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302486

7 January 2021

Cutting edge: CD4 and CD8 T cells are intrinsically different in their proliferative responses

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302486

7 January 2021

A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302486

7 January 2021

Adoptive immunotherapy with vaccine-primed lymph node cells secondarily activated with anti-CD3 and interleukin-2

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302486

7 January 2021

Localization of 111indium-labeled tumor infiltrating lymphocytes to tumor in patients receiving adoptive immunotherapy. Augmentation with cyclophosphamide and correlation with response

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302486

7 January 2021

Tumor localization of adoptively transferred indium-111 labeled tumor infiltrating lymphocytes in patients with metastatic melanoma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302486

7 January 2021

Priming of naive T cells inside tumors leads to eradication of established tumors

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302486

7 January 2021

Adenovirus-mediated CD40 ligand gene-engineered dendritic cells elicit enhanced CD8(+) cytotoxic T-cell activation and antitumor immunity

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302486

7 January 2021

Enhanced HER-2/neu-specific antitumor immunity by cotransduction of mouse dendritic cells with two genes encoding HER-2/neu and alpha tumor necrosis factor

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302486

7 January 2021

Identifiers

DOI

10.1038/SJ.GT.3302486

1 reference

Dimensions Publication ID

20 September 2017

1007693060

0 references

1 reference